EGFR-targeted drugs could be used to treat patients with glioblastomas that exhibit these characteristics in a similar fashion to some non-small-cell lung carcinomas that contain activating EGFR mutations and that show significant responses to the EGFR inhibitors erlotinib and gefitinib [303]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.